Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

MRUS

Merus N.V

May 31 • 04:00PM ET

53.24

Dollar change -4.06
Percentage change -7.09	%

Healthcare • Biotechnology • Netherlands • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IBB VHT DWAS NUSC PTH SBIO FYX FYC ESML ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.72	Insider Own	23.57%	Shs Outstand	57.83M	Perf Week	20.81%
Market Cap	3.12B	Forward P/E	-	EPS next Y	-3.41	Insider Trans	-0.17%	Shs Float	44.86M	Perf Month	13.23%
Income	-149.65M	PEG	-	EPS next Q	-0.77	Inst Own	74.22%	Short Float	7.76%	Perf Quarter	2.74%
Sales	38.34M	P/S	81.50	EPS this Y	1.19%	Inst Trans	-1.84%	Short Ratio	4.03	Perf Half Y	125.78%
Book/sh	5.95	P/B	8.94	EPS next Y	-14.93%	ROA	-35.78%	Short Interest	3.48M	Perf Year	145.12%
Cash/sh	5.75	P/C	9.26	EPS next 5Y	-	ROE	-52.79%	52W Range	19.81 - 61.61	Perf YTD	93.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.50%	ROI	-41.65%	52W High	-13.59%	Beta	1.11
Dividend TTM	-	Quick Ratio	5.23	Sales past 5Y	7.00%	Gross Margin	-	52W Low	168.82%	ATR (14)	3.34
Dividend Ex-Date	-	Current Ratio	5.23	EPS Y/Y TTM	17.30%	Oper. Margin	-434.58%	RSI (14)	58.97	Volatility	9.63% 5.24%
Employees	-	Debt/Eq	0.03	Sales Y/Y TTM	-11.73%	Profit Margin	-390.36%	Recom	1.00	Target Price	80.67
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	30.85%	Payout	-	Rel Volume	1.99	Prev Close	57.30
Sales Surprise	-17.72%	EPS Surprise	26.75%	Sales Q/Q	-41.56%	Earnings	May 08 AMC	Avg Volume	863.86K	Price	53.24
SMA20	11.57%	SMA50	17.64%	SMA200	60.16%	Trades		Volume	1,717,694	Change	-7.09%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Truist	Buy	$69
Mar-04-24	Reiterated	Needham	Buy	$42 → $65
Nov-02-23	Initiated	Canaccord Genuity	Buy	$45
Aug-21-23	Initiated	TD Cowen	Outperform
Aug-02-22	Initiated	Stifel	Buy	$38
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$45
Feb-10-22	Initiated	Needham	Buy	$45
Nov-17-21	Resumed	Guggenheim	Buy	$44
Jun-07-21	Upgrade	Citigroup	Neutral → Buy	$24 → $31
Apr-08-21	Initiated	William Blair	Outperform
Mar-16-21	Initiated	SVB Leerink	Outperform	$33
Jun-26-20	Initiated	H.C. Wainwright	Buy	$23
May-27-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16
Nov-20-19	Resumed	Guggenheim	Buy
Jun-28-19	Initiated	ROTH Capital	Buy	$20
Apr-12-19	Resumed	Guggenheim	Buy
Apr-03-19	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-27-19	Initiated	Berenberg	Buy	$35
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$28

Show Previous Ratings

May-29-24 09:30PM	Merus Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire)
08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire) -8.53%
07:00AM	Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC (GlobeNewswire)
May-27-24 11:37AM	Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data (Zacks)
04:05PM	Loading…
May-24-24 04:05PM	Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High (Investor's Business Daily) +36.12%
03:41PM	Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? (Benzinga)
01:31PM	Merus Clears Wall Street's Bar With Cancer Data (Barrons.com)
12:00PM	Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. (Barrons.com)
08:47AM	ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:01AM	ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations (FierceBiotech.com)
May-23-24 05:00PM	Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting (GlobeNewswire)
05:00PM	Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
12:50PM	Loading…
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-13-24 09:58AM	Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab (MT Newswires)
08:00AM	Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA (GlobeNewswire)
May-09-24 12:53AM	MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-08-24 04:15PM	Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update (GlobeNewswire)
May-06-24 04:05PM	Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC (GlobeNewswire)
Apr-26-24 07:58AM	Merus (MRUS) Moves 7.1% Higher: Will This Strength Last? (Zacks)
Apr-25-24 10:01AM	Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know (Zacks) +7.05%
Apr-24-24 10:00AM	Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-08-24 12:00PM	Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-24 10:11AM	Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab (FierceBiotech.com)
08:00AM	Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers (Business Wire)
06:15AM	Gilead bets on trispecifics in latest cancer drug deal (BioPharma Dive)
Mar-05-24 04:30PM	Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression (GlobeNewswire)
08:00AM	Loading…
Mar-04-24 08:00AM	Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:15PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update (GlobeNewswire)
Feb-20-24 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +5.89%
Jan-31-24 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-09-24 05:07AM	Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains? (Zacks)
Dec-28-23 09:55AM	Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Dec-12-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet (Zacks)
Dec-05-23 12:00PM	Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-04-23 12:15PM	Merus shares dip as interim lung cancer data reveal 3 patient deaths (FierceBiotech.com) -6.13%
Dec-02-23 08:40PM	Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-26-23 11:05AM	Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-23-23 09:55AM	Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Nov-07-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet (Zacks)
Nov-02-23 04:12PM	Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update (GlobeNewswire) +5.53%
Nov-01-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-26-23 10:02AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-23 07:30AM	Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer (GlobeNewswire)
Oct-17-23 05:00AM	Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-23 07:58PM	Merus Announces Business Update Conference Call (GlobeNewswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Oct-06-23 09:32AM	Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023 (GlobeNewswire)
Sep-11-23 03:45AM	GSK (GSK) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-07-23 07:36PM	Merus NV (MRUS): A Deep Dive into Its Overvalued Status (GuruFocus.com)
Aug-31-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 09:44AM	XPeng upgraded, Napco downgraded: Wall Street's top analyst calls (The Fly)
Aug-09-23 09:53PM	Merus Announces Pricing of Public Offering of Common Shares (GlobeNewswire)
04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Aug-07-23 07:15PM	Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update (GlobeNewswire)
Jul-28-23 08:00AM	Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023 (GlobeNewswire)
Jul-05-23 04:01PM	Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration (GlobeNewswire)
Jun-29-23 04:30PM	Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer (GlobeNewswire)
Jun-28-23 07:35AM	Institutional investors may overlook Merus N.V.'s (NASDAQ:MRUS) recent US$113m market cap drop as long-term gains remain positive (Simply Wall St.)
Jun-15-23 07:47AM	Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer (GlobeNewswire)
May-31-23 08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-21-23 03:28PM	7 Stocks That Wall Street Analysts Are Loving in May (InvestorPlace)
May-11-23 12:00PM	Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy (Zacks)
May-10-23 09:55AM	Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade (Zacks)
May-05-23 10:24AM	Some Confidence Is Lacking In Merus N.V.'s (NASDAQ:MRUS) P/S (Simply Wall St.) +10.58%
May-04-23 08:15PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update (GlobeNewswire)
May-02-23 10:01AM	Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-23 10:00AM	Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-23 10:15AM	Merus Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +10.07%
Apr-14-23 11:10AM	Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update (GlobeNewswire) +11.42%
11:10AM	Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
Apr-10-23 10:16AM	Merus' (NASDAQ:MRUS) investors will be pleased with their respectable 53% return over the last three years (Simply Wall St.)
Mar-14-23 04:30PM	Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
04:30PM	Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
09:08AM	We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Feb-28-23 04:25PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-23-23 11:37AM	Is a Surprise Coming for Merus (MRUS) This Earnings Season? (Zacks)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-15-23 06:22AM	Is Merus N.V. (NASDAQ:MRUS) Trading At A 21% Discount? (Simply Wall St.)
Feb-10-23 03:44AM	Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength? (Zacks)
Feb-01-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-19-23 11:06AM	14 Small-Cap Stocks with High Potential (Insider Monkey)
05:37AM	With 62% ownership, Merus N.V. (NASDAQ:MRUS) boasts of strong institutional backing (Simply Wall St.)
Jan-09-23 06:05AM	CORRECTING and REPLACING --Merus Provides 2023 Outlook (GlobeNewswire)
Jan-08-23 09:00AM	Merus Provides 2023 Outlook (GlobeNewswire)
Nov-09-22 08:00AM	Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
07:09AM	Merus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-03-22 09:05AM	Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -25.02%
07:51AM	Merus Announces Financial Results for the Third Quarter and Provides Business Update (GlobeNewswire)
Oct-26-22 04:00AM	Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.81%
Oct-12-22 02:19PM	Analyst Casts Doubts On Merus' Lung Candidate Safety Profile (Benzinga) +9.73%
07:00AM	Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shuman Harry	VP Controller, PAO	Dec 19 '23	Sale	26.68	115	3,068	7,002	Dec 20 04:05 PM
Silverman Peter B.	COO & GC	Dec 15 '23	Sale	25.00	22,386	559,650	0	Dec 18 05:15 PM
Shuman Harry	VP Controller, PAO	Dec 08 '23	Sale	24.44	250	6,110	7,117	Dec 12 04:04 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Option Exercise	0.00	2,500	0	7,942	Dec 04 04:05 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Sale	24.58	575	14,133	7,367	Dec 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRUS

Merus N.V

Upgrade your FINVIZ experience